VAXINANO
Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
VAXINANO
Industry:
Biotechnology Clinical Trials Delivery Pharmaceutical
Founded:
2016-01-01
Address:
Lille, Nord-Pas-de-Calais, France
Country:
France
Website Url:
http://www.vaxinano.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Google Maps Content Delivery Network Font Awesome IPv6 JsDelivr Apache Microsoft Exchange Online
Similar Organizations
Acyte Biotech
Acyte Biotech is a biotechnology company that specializes in proprietary technologies in mammalian cell engineering and cell culture.
Atlas Biotechnology
Atlas Biotechnology is biotechnology research specializing in medical care and pharmaceuticals.
Biosphere
Biosphere is a biotech company specialized in fermentation process development and contract manufacturing.
Diabetology
Diabetology is an award winning clinical stage biopharmaceutical company
In-Cell-Art
This company is specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxiยฎ.
Vipragen Biosciences
Vipragen Biosciences is a biotechnology company that specializes in Pharmaceuticals & drug development.
Current Employees Featured
Founder
Investors List
Eurasante
Eurasante investment in Non Equity Assistance - Vaxinano
Official Site Inspections
http://www.vaxinano.com
- Host name: ip85-215-251-62.pbiaas.com
- IP address: 85.215.251.62
- Location: Berlin Germany
- Latitude: 52.5174
- Longitude: 13.3985
- Timezone: Europe/Berlin
- Postal: 12529
More informations about "Vaxinano"
Vaxinano - Crunchbase Company Profile & Funding
Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and โฆSee details»
Vaxinano - LinkedIn
Vaxinano | 1,395 followers on LinkedIn. Developing life-changing vaccines and immunotherapies | Vaxinano is a clinical-stage biotechnology company, developing a new generation of nasally ...See details»
VAXINANO - Societe.com
VAXINANO, société par actions simplifiée, au capital social de 73690,00 EURO, dont le siège social est situé au 84 RUE DU DOCTEUR YERSIN, 59120 LOOS, immatriculée au Registre โฆSee details»
Vaxinano Company Profile: Overview and Full News Analysis
Vaxinano, a biotech company specializing in the development of prophylactic and therapeutic nasal vaccines, has successfully raised 6 million in a funding round . The round was led by โฆSee details»
VAXINANO Company Profile | LOOS, HAUTS DE FRANCE, France
Find company research, competitor information, contact details & financial data for VAXINANO of LOOS, HAUTS DE FRANCE. Get the latest business insights from Dun & Bradstreet.See details»
Vaxinano Secures โฌ6 Million in Funding to Advance Nasal Vaccines โฆ
Oct 29, 2024 Vaxinano is a French-based biotech company developing nasal vaccines to address unmet needs in infectious diseases. Its innovative platform is based on an adjuvant โฆSee details»
Vaxinano Raises โฌ6M in Funding - finsmes.com
Oct 30, 2024 Vaxinan o, a Lille, France-based biotech company specializing in the development of prophylactic and therapeutic nasal vaccines, raised โฌ6M in funding.. The round was led by โฆSee details»
Vaxinano SAS (Vaxinano SAS) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅ โฆ
About Vaxinano: Vaxinano is a French-based biotech company developing nasal vaccines to address unmet needs in infectious diseases. Its innovative platform is based on an adjuvant โฆSee details»
Vaxinano S.A.S. - BioCentury Company Profiles - BCIQ
Vaxinano S.A.S. - BioCentury Company Profiles for the biopharma industrySee details»
Vaxinano lève 6 millions d'euros pour développer sa plateforme de ...
Oct 29, 2024 Vaxinano, biotech lilloise, développe des vaccins nasaux pour répondre aux besoins croissants en matière de maladies infectieuses. Sa plateforme innovante, sans โฆSee details»
Vaxinano lève 6 millions d'euros pour son vaccin à administration โฆ
Oct 31, 2024 La start-up lilloise Vaxinano, installée au sein du parc Eurasanté, vient de boucler un tour de table à hauteur de 6 millions dโeuros, pour soutenir le développement de son vaccin โฆSee details»
Vaxinano on LinkedIn: FDA approves first flu vaccine that can be โฆ
The U.S. Food and Drug Administration (FDA) recently announced its groundbreaking approval of FluMist, a nasal spray flu vaccine, making it the first influenza vaccine that individuals can self ...See details»
Maltodextrin-Nanoparticles as a Delivery System for Nasal โฆ
Authors F.F., A.S. and D.B. was employed by the company Vaxinano. The remaining authors declare that the research was conducted in the absence of any commercial or financial โฆSee details»
Vaxinano announces exclusive licensing agreement for canine ...
Nov 12, 2024 Vaxinano develops nasal vaccines based on Stellar-NP, a unique vaccine delivery system designed to address unmet needs in infectious disease. It offers rapid, efficient and โฆSee details»
Effective immuno-therapeutic treatment of Canine Leishmaniasis
The study was founded by the company Vaxinano, and FF, AS and DB are employees at Vaxinano. AG is consultant for Vaxinano. Vaxinano played a role in the study design, the data โฆSee details»
Leishmaniasis vaccine - Vaxinano - AdisInsight - Springer
15 Mar 2024 Preclinical developement in Leishmaniasis in France (Intranasal) before March 2024 (Vaxinano website, March 2024) 17 Aug 2021 Immunogenicity data from a preclinical trial in โฆSee details»
Vaxinano - Company Profile - Tracxn
Oct 30, 2024 Vaxinano ranks 112th among 632 active competitors. 186 of its competitors are funded while 92 have exited. Overall, Vaxinano and its competitors have raised over $9.91B in โฆSee details»
Vaxinano - Founders and Board of Directors - Tracxn
Oct 21, 2024 Vaxinano founders & board of directors. Prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets. 2016 โข Lille (France) โข Funding RaisedSee details»
Toxoplasmosis vaccine - Vaxinano - AdisInsight - Springer
If your organization has a subscription, there are several access options, even while working remotely: Working within your organizationโs network Login with username/password or try to โฆSee details»
Vaxinano - Raised $6.48M Funding from 6 investors - Tracxn
3 days ago Vaxinano has raised a total funding of $6.48M over 2 rounds from 6 investors. Investors include Bpifrance, Nord France Amorquage and 4 others. Their latest funding round โฆSee details»